| Stock Price Performance - 12 Largest Positive One-Day Changes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day of Event |
After Event Date (Not Including Day of Selected Event) |
||||||||||||||||
| Date | Note | Day-Of Move | Opening Gap | % Open-to-High | % Open-to-Low | Drift Open-to-Close | 1 Day | 2 Days | 3 Days | 1 Week | 2 Weeks | ||||||
| 16-Dec-2024 [Stock +29.0%] |
Headline Sangamo surges 24% after Roche ends development of hemophilia A gene therapy (16-Dec-2024, 12:00 AM Seeking Alpha News) |
+29.0% | |||||||||||||||
| 5-Nov-2024 [Stock +24.1%] |
Press Release Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast (4-Nov-2024, 4:15 PM Business Wire) |
+24.1% | |||||||||||||||
| 28-Oct-2024 [Stock +36.0%] |
+36.0% | ||||||||||||||||
| 23-Oct-2024 [Stock +27.3%] |
Press Release Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 (22-Oct-2024, 8:05 AM Business Wire) HeadlineSangamo stock rallies 37% on FDA update for Fabry disease drug (22-Oct-2024, 12:00 AM Seeking Alpha News) |
+27.3% | |||||||||||||||
| 22-Oct-2024 [Stock +32.5%] |
Press Release Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 (22-Oct-2024, 8:05 AM Business Wire) HeadlineSangamo stock rallies 37% on FDA update for Fabry disease drug (22-Oct-2024, 12:00 AM Seeking Alpha News) |
+32.5% | |||||||||||||||
| 6-Aug-2024 [Stock +28.9%] |
Day Before EarningsSGMO released earnings 6-Aug-2024 AMCPress Releases Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases (6-Aug-2024, 8:05 AM Business Wire) Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results (6-Aug-2024, 4:01 PM Business Wire) HeadlinesRoche, Sangamo ink licensing deal for neuro drugs (6-Aug-2024, 12:00 AM Seeking Alpha News) Sangamo Therapeutics GAAP EPS of -$0.18 misses by $0.03, revenue of $0.3M misses by $7.96M (6-Aug-2024, 12:00 AM Seeking Alpha News) |
+28.9% | |||||||||||||||
| 2-Aug-2024 [Stock +23.6%] |
+23.6% | ||||||||||||||||
| 26-Jul-2024 [Stock +28.7%] |
Headline Sangamo rallies for third day in wake of positive gene therapy results (26-Jul-2024, 12:00 AM Seeking Alpha News) |
+28.7% | |||||||||||||||
| 24-Jul-2024 [Stock +39.5%] |
Press Release Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate (24-Jul-2024, 6:55 AM Business Wire) HeadlinePfizer/ Sangamo gene therapy for hemophilia A succeeds in late-stage trial (24-Jul-2024, 12:00 AM Seeking Alpha News) |
+39.5% | |||||||||||||||
| 16-Feb-2024 [Stock +31.4%] |
+31.4% | ||||||||||||||||
| 15-Feb-2024 [Stock +39.3%] |
+39.3% | ||||||||||||||||
| 12-Feb-2024 [Stock +40.1%] |
Press Release Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease (12-Feb-2024, 8:05 AM Business Wire) |
+40.1% | |||||||||||||||
| Simple Average Returns - 12 Largest Positive One-Day Changes | |||||||||||||||||
| Avg Return | |||||||||||||||||
| Positive Occurrences | |||||||||||||||||
| Negative Occurrences | |||||||||||||||||
| Absolute Average Returns - 12 Largest Positive One-Day Changes | |||||||||||||||||
| Abs Avg Return | |||||||||||||||||
| Max Abs Return | |||||||||||||||||
| Min Abs Return | |||||||||||||||||
| Median, Minimum, and Maximum Returns - 12 Largest Positive One-Day Changes | |||||||||||||||||
| Median Return | |||||||||||||||||
| Max Positive Return | |||||||||||||||||
| Max Negative Return | |||||||||||||||||